Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmaceutical Equivalents

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ghrelin and the gut.

Endocrine development·2013

Same author

Old and new targets for prokinetic drugs: motilin and ghrelin receptors.

European review for medical and pharmacological sciences·2008

Same author

Endogenous and exogenous ghrelin enhance the colonic and gastric manifestations of dextran sodium sulphate-induced colitis in mice.

Neurogastroenterology and motility·2008

Same author

Effect of peripheral obestatin on food intake and gastric emptying in ghrelin-knockout mice.

British journal of pharmacology·2008

Same author

Theophylline and its metabolites produce a stimulating cholinergic effect on the small intestine and a nonadrenergic noncholinergic relaxing effect on the colon: a comparative study in the rabbit intestine.

Journal of veterinary pharmacology and therapeutics·2007

Same author

Effect of peripheral obestatin on gastric emptying and intestinal contractility in rodents.

Neurogastroenterology and motility·2007

Search research articles

Related Experiment Video

Updated: Feb 7, 2026

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Published on: March 4, 2021

GM-611 (Chugai Pharmaceutical).

¹Gasthuisberg ON, Gut Hormone Laboratory, Leuven, Belgium. theo.peeters@med.kuleuven.ac.be

Current Opinion in Investigational Drugs (London, England : 2000)

|September 22, 2001

Summary

This summary is machine-generated.

GM-611, a motilin receptor agonist, shows promise for treating gastric motility disorders. This erythromycin derivative stimulates gastrointestinal peristalsis and is currently in Phase II trials for reflux esophagitis.

More Related Videos

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

Published on: August 11, 2017

Coherent anti-Stokes Raman Scattering CARS Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Coherent anti-Stokes Raman Scattering CARS Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Published on: July 4, 2014

Related Experiment Videos

Last Updated: Feb 7, 2026

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Published on: March 4, 2021

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

Published on: August 11, 2017

Coherent anti-Stokes Raman Scattering CARS Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Coherent anti-Stokes Raman Scattering CARS Microscopy Visualizes Pharmaceutical Tablets During Dissolution

Published on: July 4, 2014

Area of Science:

Gastroenterology
Pharmacology

Background:

Gastric motility disorders affect millions globally.
Current treatments have limitations, necessitating novel therapeutic approaches.
Diabetic gastroparesis and reflux esophagitis represent significant unmet medical needs.

Purpose of the Study:

To investigate the therapeutic potential of GM-611, an erythromycin derivative, for gastrointestinal motility disorders.
To elucidate the mechanism of action of GM-611.
To assess the efficacy of GM-611 in clinical trials.

Main Methods:

GM-611 was investigated as a motilin receptor agonist.
Preclinical studies involved assessing effects on rabbit duodenal smooth muscle depolarization.
Clinical trials (Phase II) were conducted for reflux esophagitis in the US.

Main Results:

GM-611 stimulates and promotes peristalsis in the stomach and gastrointestinal tract.
The drug induced a dose-dependent sustained depolarization of rabbit duodenal smooth muscle.
Activation of monovalent cation-selective channels was implicated in the observed depolarization.

Conclusions:

GM-611 represents a novel therapeutic agent for gastric motility disorders.
Its mechanism involves direct stimulation of gastrointestinal motility.
Positive clinical trial outcomes could lead to significant market potential.